Gastroenterology News

CHICAGO — The microbiome profile of early-onset pancreatic adenocarcinoma is distinct from that of average-onset disease, according to findings presented at ASCO Annual Meeting.

One of the most important questions physicians will need to answer is whether they will hire a financial advisor to help them manage their wealth or do it themselves.

WASHINGTON — Maintenance Skyrizi 180 mg and 360 mg was superior to placebo in achieving clinical remission among patients with moderately to severely active ulcerative colitis who responded to 12-week induction therapy, according to data.

CHIGAGO — Perioperative chemotherapy improved OS in patients with locally advanced esophageal adenocarcinoma compared with chemoradiation prior to surgery, results form a randomized phase 3 trial presented at ASCO Annual Meeting showed.

CHICAGO — Combination immunotherapy significantly improved outcomes vs. first-line chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer, according to study results.

CHICAGO — Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced HER2-amplified biliary tract cancer, according to results of the phase 2B HERIZON-BTC-01 study presented at ASCO Annual Meeting.

CHICAGO — An AI-guided navigation workflow helped identify patients earlier in the diagnostic timeline than the traditional cancer referral process while reducing times to biopsy, follow-up and treatment initiation, study results showed.

BOSTON — Accumulating sedentary time during childhood was associated with increased risk for liver disease in young adulthood, but boosting light physical activity may lessen the risk, according to data presented at ENDO 2024.

WASHINGTON — Entyvio is “safe and effective” for maintaining sustained steroid-free remission at 1 year in children with inflammatory bowel disease, more so in those with ulcerative colitis vs. Crohn’s disease, according to a researcher.

WASHINGTON — Among adults with eosinophilic esophagitis, weight gain while undergoing dietary therapy was associated with poor treatment response, regardless of baseline weight status, according to data presented at Digestive Disease Week.